Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Aug 26;50(4):221-227.
doi: 10.4274/tjo.galenos.2020.97415.

Evaluation of the Effect of Proptosis on Choroidal Thickness in Graves' Ophthalmopathy

Gamze Yıldırım  1 , Esra Şahlı  2 , Mehmet Numan Alp  3
Affiliations

Evaluation of the Effect of Proptosis on Choroidal Thickness in Graves' Ophthalmopathy

Gamze Yıldırım et al. Turk J Ophthalmol. .

Abstract

Objectives: To evaluate the effect of proptosis on choroidal thickness in patients with Graves' ophthalmopathy.

Materials and methods: Twenty-five eyes of 25 Graves' patients with proptosis, 25 eyes of 25 Graves' patients without proptosis, and 25 eyes of 25 healthy individuals were included in this prospective study. The subfoveal choroidal thickness and choroidal thicknesses at 6 points from the fovea at 500 μm intervals were measured by Cirrus HD-OCT. All measurements were compared among the proptosis, non-proptosis, and control groups and the active, inactive, and control groups.

Results: The mean subfoveal choroidal thickness in the proptosis group was 289.7±68.5 μm, 322.5±55.8 μm in the non-proptosis group, and 316.1±63.0 μm in the control group. The mean nasal choroidal thickness was 260.5±63.5 μm in the proptosis group, 293.9±57.9 μm in the non-proptosis group, and 279.5±63.1 μm in the control group. The mean temporal choroidal thickness was 261.8±60.9 μm in the proptosis group, 289.0±51.8 μm in the non-proptosis group, and 287.8±56.2 μm in the control group. Mean choroidal thickness was 264.7±58.5 μm in the proptosis group, 296.2±47.5 μm in the non-proptosis group, and 288.3±55.1 μm in the control group. There were no statistically significant differences among the groups with respect to choroidal thickness measurements (p>0.05).

Conclusion: No significant difference in choroidal thickness was detected between Graves' patients with and without proptosis and the controls. There was no effect of clinical activation on choroidal thickness.

Keywords: Graves’ ophthalmopathy; choroidal thickness; optical coherence tomography; proptosis.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: No conflict of interest was declared by the authors.

References

    1. Bartalena L, Pinchera A, Marcocci C. Management of Graves’ ophthalmopathy: reality and perspectives. Endocr Rev. 2000;21:168–199. - PubMed
    1. Ginsberg J. Diagnosis and management of Graves’ disease. CMAJ. 2003;168:575–585. - PMC - PubMed
    1. Gharib S, Moazezi Z, Bayani MA. Prevalence and severity of ocular involvement in Graves’ disease according to sex and age: A clinical study from Babol, Iran. Caspian J Intern Med. 2018;9:178–183. - PMC - PubMed
    1. Bartley GB, Fatourechi V, Kadrmas EF, Jacobsen SJ, Ilstrup DM, Garrity JA, Gorman CA. Clinical features of Graves’ ophthalmopathy in an incidence cohort. Am J Ophthalmol. 1996;121:284–290. - PubMed
    1. Şahlı E, Gündüz K. Thyroid-associated ophthalmopathy. Turk J Ophthalmol. 2017;47:94–105. - PMC - PubMed

LinkOut - more resources